Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Choy, Ernest; Groves, Lara; Sugrue, Daniel; Hurst, Michael; Houghton, John; Venkatachalam, Srinivasan; Patel, Yusuf I.; Maxwell, James R.; Pollock, Kevin G.; Henning, Sadie

doi:10.1186/s41927-020-00173-0

BMC Rheumatology

Table 5 Incremental change in DAS28-ESR and DAS28-CRP at 6 months after LOT initiation

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Antibody Status	From 6 months
	Abatacept			Other bDMARD			Incremental difference
	Cohort (n)	Mean	95% CI	Cohort (n)	Mean	95% CI	LS Mean	95% CI	P value
DAS28-ESR
All patients	92	−1.59	−1.95,-1.23	145	−1.56	− 1.87,-1.24	− 0.04	− 0.45,0.38	0.86
ACPA+	48	−1.58	−2.09,-1.06	60	− 1.21	−1.71,-0.71	−0.37	− 0.97,0.24	0.24
ACPA-	20	−2.03	−2.96,-1.09	30	−1.92	−2.79,-1.05	− 0.11	− 0.94,0.73	0.81
RF+	65	−1.57	−2.00,-1.15	94	−1.39	− 1.78,-1.00	−0.19	−0.69,0.32	0.47
RF-	21	−1.73	−2.59,-0.86	34	−2.01	− 2.83,-1.18	0.28	−0.51,1.08	0.49
ACPA+/RF+	45	−1.58	−2.10,-1.05	47	− 1.10	− 1.61,-0.59	−0.48	− 1.11,0.15	0.14
ACPA+/RF-	^a	−2.59	−36.06,30.88	^a	−2.35	− 54.75,50.05	−0.24	−5.27,4.79	0.93
ACPA−/RF+	^a	−2.55	−4.73,-0.37	6	−1.28	−3.22,0.66	− 1.27	− 3.14,0.60	0.22
ACPA−/RF-	16	−1.88	−2.82,-0.93	24	−2.02	−2.91,-1.12	0.14	−0.76,1.04	0.76
DAS28-CRP
All patients	116	−1.55	− 1.82,-1.28	106	−1.39	− 1.68,-1.09	−0.16	− 0.50,0.18	0.36
ACPA+	48	−1.49	− 1.94,-1.05	42	−1.20	− 1.71,-0.69	−0.29	− 0.83,0.24	0.28
ACPA-	11	−1.28	−2.22,-0.35	21	−1.14	−1.88,-0.40	−0.14	− 1.22,0.93	0.80
RF+	87	−1.66	−1.97,-1.35	69	−1.43	− 1.80,-1.06	− 0.23	− 0.64,0.18	0.27
RF-	17	−1.25	−2.04,-0.47	25	−1.48	−2.21,-0.76	0.23	−0.67,1.13	0.62
ACPA+/RF+	44	−1.50	−1.94,-1.06	38	−1.04	− 1.55,-0.53	−0.46	−1.02,0.11	0.12
ACPA+/RF-	^a	−2.06	−13.11,9.00	^a	−2.80	−19.06,13.46	0.74	−2.47,3.96	0.69
ACPA−/RF+	^a	−3.10	−4.32,-1.89	6	−0.88	−1.97,0.22	−2.22	− 3.64,-0.81	0.01
ACPA−/RF-	6	0.18	−1.02,1.38	15	−1.11	−1.94,-0.29	1.30	−0.08,2.67	0.07

bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation rate; n is the number of patients with a DAS score recorded at LOT initiation and at 6 months
^aCells suppressed due to small numbers

Back to article page

ISSN: 2520-1026

Contact us

Submission enquiries: bmcrheumatology@biomedcentral.com
General enquiries: ORSupport@springernature.com